Phase I/II study to evaluate the efficacy and safety of PAZOPANIB in combination with TEMOZOLOMIDE as maintenance therapy in Glioblastoma patients undergoing surgery and subsequently treated with induction radiotherapy-TEMOZOLOMIDE

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-510960-22-00

Enrollment

Registered

2024-04-22

Start date

2015-06-25

Completion date

Unknown

Last updated

2025-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gliobastoma

None listed

Sex/Gender

All

Age

18 Years to No maximum

France

None listed

Source: EU CTIS · Data processed: Feb 4, 2026